Fresh Frozen Plasma Dosing in Factor XI Deficiency
For Factor XI deficiency, transfuse 5-20 mL/kg/day of fresh frozen plasma starting the day before surgery and continuing for 10-14 days postoperatively, with the specific dose and duration adjusted based on bleeding site risk—higher-risk sites (urological, nasopharyngeal, cardiac) require the upper end of this range, while lower-risk procedures may use 5-7.5 mL/kg perioperatively.
Dosing Algorithm by Bleeding Risk
High-Risk Sites (Urological, Cardiac, Nasopharyngeal Surgery)
- Preoperative: 5-20 mL/kg FFP starting 24 hours before surgery 1
- Intraoperative: Continue FFP to maintain Factor XI levels ≥30% (0.3 U/mL) 1
- Postoperative: Continue 5-20 mL/kg/day for 10-14 days 1
- Target: Maintain Factor XI activity at minimum 30% for adequate hemostasis 1
The evidence from urological surgery demonstrates that this prolonged regimen (10-14 days) prevented complications in all 5 patients with severe Factor XI deficiency, while 1 of 3 patients who did not receive adequate transfusion experienced postoperative bleeding 1.
Moderate-Risk Sites (Abdominal Surgery, Spinal Surgery)
- Preoperative: 4 units (approximately 5 mL/kg) FFP 24 hours before surgery 2, 3
- Intraoperative: Additional 2-4 units during surgery 2, 3
- Monitoring: Check aPTT morning of surgery (target <70 seconds) and intraoperatively (target ≤60 seconds) 3
For sigmoid colon resection, 5 mL/kg preoperatively plus 2 units intraoperatively resulted in uneventful surgery with no bleeding 2. For cervical spine surgery, 4 units preoperatively (reducing aPTT from 139.8 to 70.5 seconds) plus 4 units intraoperatively (aPTT 60 seconds) prevented complications 3.
Lower-Risk Cardiac Surgery with Bypass
- Perioperative: 5-7.5 mL/kg FFP just before surgery and just before cessation of cardiopulmonary bypass 4
- Guidance: Use point-of-care viscoelastic testing (ROTEM/TEG) to guide dosing 4, 5
- Precision approach: Small, targeted doses guided by real-time coagulation monitoring resulted in no significant bleeding and avoided over-transfusion 4
Critical Monitoring Parameters
Laboratory targets:
- Factor XI activity ≥30% (0.3 U/mL) is the minimum threshold for adequate hemostasis 1
- aPTT should normalize or approach normal range (target <70 seconds preoperatively, ≤60 seconds intraoperatively) 3
- Consider TEG/ROTEM for real-time assessment, particularly in cardiac surgery 4, 5
Important Caveats
Bleeding risk in Factor XI deficiency is unpredictable: Unlike hemophilia A/B, bleeding severity does not correlate reliably with Factor XI levels 1, 6. Even patients with severe deficiency (<1% activity) may not bleed spontaneously but are at high risk with surgery, particularly at sites with high fibrinolytic activity (nasopharyngeal, oropharyngeal, genitourinary) 6, 7.
FFP limitations: Fresh frozen plasma has a short half-life and requires large volumes, which can lead to volume overload 8. The 2025 Anaesthesia guidelines note that FFP is indicated for major hemorrhage and specific coagulation factor deficiencies, but emphasize that prophylactic FFP for abnormal coagulation tests in stable patients is not supported by good evidence 8. However, Factor XI deficiency represents a specific hereditary deficiency where prophylactic FFP is justified based on the surgical bleeding risk.
Alternative agents: If FFP fails or is insufficient (particularly in cardiac surgery with ongoing bleeding), consider 4-factor prothrombin complex concentrate combined with FFP 7. Tranexamic acid, Factor XI concentrates (not available in US/UK), or recombinant Factor VIIa are additional options 6.
Population consideration: Factor XI deficiency is particularly prevalent in Ashkenazi Jews of Eastern European origin, with relatively high gene frequency 1. Screen with aPTT in this population before surgery.